Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer - PubMed (original) (raw)
doi: 10.1002/gcc.20854. Epub 2011 Feb 8.
Affiliations
- PMID: 21305640
- DOI: 10.1002/gcc.20854
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Cecily P Vaughn et al. Genes Chromosomes Cancer. 2011 May.
Abstract
Mutational analysis of KRAS codons 12 and 13 is standard for patients with metastatic colorectal cancer since mutations in these codons predict lack of response to anti-EGFR therapies. However, even among patients whose tumors are wildtype for KRAS codons 12 and 13, only a subset respond to therapy. Since additional activating mutations downstream of EGFR may also play a role in treatment resistance, we sought to establish the frequency of these mutations. We evaluated 2121 colorectal tumors for mutations in codons 12 and 13 of the KRAS gene. A subset of these samples, comprised of 513 samples wildtype for KRAS codons 12 and 13, were tested for mutations in codons 61 and 146 of KRAS, codon 600 of BRAF, and codons 12, 13, and 61 of NRAS. Mutation status was determined by targeted pyrosequencing. Mutations in KRAS codon 12 or 13 were identified in 900/2121 (42.4%) samples. Of the 513 wildtype samples tested for additional mutations, 78 samples were mutant for BRAF, 19 for KRAS codon 61, 17 for KRAS codon 146, and 26 for NRAS. In total, 140/513 (27.3%) tumors wildtype for KRAS codons 12 and 13 harbored a mutation in another of the RAS pathway genes. While further study is needed to determine the full therapeutic implications of mutations in these codons, mutational testing of these codons may be useful for identifying a significant proportion of patients who may also be resistant to anti-EGFR therapies.
2011 Wiley-Liss, Inc.
Similar articles
- Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M. Seth R, et al. Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26. Gut. 2009. PMID: 19474002 - [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y, Ying JM, Qiu T, Shan L, Guo L, Lü N. Ling Y, et al. Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):590-4. doi: 10.3760/cma.j.issn.0529-5807.2012.09.004. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 23157825 Chinese. - Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A. Schirripa M, et al. Int J Cancer. 2015 Jan 1;136(1):83-90. doi: 10.1002/ijc.28955. Epub 2014 May 28. Int J Cancer. 2015. PMID: 24806288 - [Predictive biomarkers for anti-EGFR antibodies].
Bando H, Yoshino T. Bando H, et al. Gan To Kagaku Ryoho. 2012 Nov;39(11):1618-25. Gan To Kagaku Ryoho. 2012. PMID: 23152013 Review. Japanese. - Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Heinemann V, et al. Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Cancer Treat Rev. 2009. PMID: 19117687 Review.
Cited by
- Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy FM, Turner AL, Marensi V, MacEwan DJ. Healy FM, et al. Front Pharmacol. 2024 Sep 20;15:1441938. doi: 10.3389/fphar.2024.1441938. eCollection 2024. Front Pharmacol. 2024. PMID: 39372214 Free PMC article. Review. - Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer.
Shan H, Tian G, Zhang Y, Qiu Z. Shan H, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2392341. doi: 10.1080/15384047.2024.2392341. Epub 2024 Aug 20. Cancer Biol Ther. 2024. PMID: 39164192 Free PMC article. Review. - Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Tomuleasa C, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w. Signal Transduct Target Ther. 2024. PMID: 39138146 Free PMC article. Review. - Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z, Pirestani M, Arefian E, Gojani G, Kavousinasab N, Karimi P, Deilami A, Abrehdari-Tafreshi Z. Mosaferi Z, et al. J Gastrointest Cancer. 2024 Sep;55(3):1134-1143. doi: 10.1007/s12029-024-01064-0. Epub 2024 May 6. J Gastrointest Cancer. 2024. PMID: 38709419 - BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer.
Jenkins LJ, Luk IY, Chionh F, Tan T, Needham K, Ayton J, Reehorst CM, Vukelic N, Sieber OM, Mouradov D, Gibbs P, Williams DS, Tebbutt NC, Desai J, Hollande F, Dhillon AS, Lee EF, Merino D, Fairlie WD, Mariadason JM. Jenkins LJ, et al. Cell Death Dis. 2024 Mar 1;15(3):183. doi: 10.1038/s41419-024-06478-z. Cell Death Dis. 2024. PMID: 38429301 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous